Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,739.60
(
-0.24%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.99
(
3.19%
)
Bitcoin
70,251.74
(
-1.39%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 117609

Wednesday, 05/09/2012 2:07:30 PM

Wednesday, May 09, 2012 2:07:30 PM

Post# of 257257
Biolex sells Locteron (a formulation of interferon for HCV) and its LEX production platform for an undisclosed sum:

http://www.marketwatch.com/story/biolex-sells-lex-system-to-synthon-and-initiates-sale-of-locteronr-2012-05-07

When investors thought interferon would remain a mainstay of HCV therapy for many years to come, Locteron was considered one of the most promising late-stage HCV programs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now